Magnesium Treatment in Hypoparathyroidism

Hypoparathyroidism Clinical Trial

Official title:

Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00824226
• Other study ID #: UT296
• Status: Completed
• Phase: N/A
• First received: January 15, 2009
• Last updated: August 26, 2011
• Start date: January 2009
• Est. completion date: August 2011

Study information

• Verified date: August 2011
• Source: University of Tartu
• Contact: n/a
• Is FDA regulated: No
• Health authority: Estonia: The State Agency of Medicine
• Study type: Interventional

Clinical Trial Summary

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• primary or secondary hypoparathyroidism

• treatment with calcium plus vitamin D analogue

• ionized calcium 1,0-1,29 mmol/L

• magnesium level 0,7-1,05 mmol/L

• TSH 0.1- 10 imU/L

Exclusion Criteria:

• any other disease known to influence plasma Ca level

• pregnancy

• creatinine > 150 microM/L

• patient has used supplementary magnesium within 2 previous months

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypoparathyroidism

Intervention

Dietary Supplement:
• magnesium
magnesium 350 mg tablets once a day for 3 weeks

Locations

Country	Name	City	State
Estonia	Tartu University Hospital	Tartu

Sponsors (1)

Lead Sponsor	Collaborator
University of Tartu

Country where clinical trial is conducted

Estonia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Calcium level at the end of magnesium treatment compared to pretreatment level		3 weeks	No
Secondary	Calcium level after stopping treatment compared to the level at the end of magnesium treatment		2 weeks	No